News
26th April 2021

Free to Register – Cancer Progress 2021 Conference [Virtual]

Cello Health’s Cancer Progress conference will take place on May 4-6, 2021, virtually. Thanks to the generosity of the event sponsors, it is free to register and access partnering. Cancer Progress is now in its 32nd year and it is…

Free to Register – Cancer Progress 2021 Conference [Virtual]

Cello Health’s Cancer Progress conference will take place on May 4-6, 2021, virtually. Thanks to the generosity of the event sponsors, it is free to register and access partnering.

Cancer Progress is now in its 32nd year and it is the only oncology conference that facilitates discussions of scientific progress within the context of development, regulatory, clinical, commercial and investment perspectives over three days of provocative, informative panel discussions. Pivotal topics, frank discussions, vigorous debate, opportunities for audience questions and comments, and, for the first time ever, a partnering platform to enable meaningful connections and meetings with innovators, developers, and investors. By attending the Cancer Progress conference, you will access great content such as the Day One Panel: Climbing the Highest Peak: Targeting PD-1/L1 Failures in Solid Tumors (see below for additional details on this panel).

Check out the video below to hear directly from Cello Health BioConsulting’s Jeff Bockman, PhD, EVP (Oncology Practice Head) on the unique value of the Cancer Progress conference.

 

 

The Day One Panel Climbing the Highest Peak: Targeting PD-1/L1 Failures in Solid Tumors will be moderated by Cello Health BioConsulting’s Jeff Bockman, PhD, EVP and James Lee, PhD, Principal, Oncology Lead. They will be joined by the an esteemed group of panelists including:

Neil Brewis, PhD, F-star Therapeutics, Inc.
Michael Curran, PhD, Assoc. Prof, Dept. of Immunology, MD Anderson Cancer Center
Kapil Dhingra , MD, KAPital Consulting LLC
Laurent Levy, PhD, Nanobiotix
Michael J. Newman, Ph.D., CEO, Decoy
Thomas Schuetz, MD, PhD, CEO and Co-founder, Compass Therapeutics Inc.
Emmett Schmidt, MD, PhD, VP, Clinical Oncology, Lead, External Collaborations Oncology Early Development, Merck
Mai-Britt Zocca, PhD, Founder & CEO, IO Biotech

The above panel will focus on perhaps the most active area of drug development in oncology: the effort to improve upon outcomes with checkpoint inhibitors (CPI) by combining agents post failure of the checkpoint with the CPI to resensitize the tumor microenvironment and enable patients to continue to derive benefit from immunotherapies.

Click to Register and See Full Agenda:
https://cancerprogressbycellohealth.com/registration/

Recent Related Articles

Using Technology to Keep Up With the Latest Scientific Information
06 October 2021
Using Technology to Keep Up With the Latest Scientific Information

Suffering from scientific information overload (SIO)? Nowadays, scientific information is bombarding us from all angles, leading to information overload which, according to the Information Overload Research Group, is also referred to as “information glut”, “infoxication”, or “data smog” and “occurs... Read more

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us